Eris Lifesciences Ltd is a publicly listed Indian pharmaceutical company and a leading player in the domestic branded formulation market. Ranked #21 in the IPM (Indian Pharmaceutical Market), Eris has established a leading presence in its core cardio-metabolic franchise in just 17 years from inception. It is the youngest among the top 20 companies in the Indian Pharmaceutical Market.
"We began our journey 17 years ago in 2007 with the vision to make a meaningful impact in the management of chronic lifestyle related diseases." The company has built a comprehensive portfolio focused on chronic and sub-chronic therapies, establishing itself as a significant player in the Indian pharmaceutical landscape. Eris Lifesciences Ltd is the only publicly listed Indian pharmaceutical company with a pure-play domestic branded formulations business model.
Eris operates as a fully integrated pharmaceutical company with a strong focus on domestic branded formulations. "We have a fully integrated business model with our WHO GMP compliant manufacturing facility in Guwahati catering to 74% of our revenue. Our pan-India distribution network of over 2,100 stockists and 5,00,000+ chemists gives us a seamless presence across the nation."
The company's operations are supported by a substantial workforce, with over 4000 employees working out of its corporate offices in Ahmedabad and Mumbai, the field, and its Guwahati facility. This comprehensive infrastructure enables Eris to maintain strong market reach and operational efficiency across India.
Diabetes care (Oral + Insulin) is our flagship therapy contributing to 32% of our branded formulations revenue, and in our Oral Diabetes covered market, we rank among the Top-6 companies in India in revenue share as well as prescription share. Eris is also successfully diversifying its business with 4 emerging therapies (Dermatology, Neuropsychiatry, Women's Health, and Nephrology) accounting for 29% of its revenue.
The company's product portfolio spans multiple therapeutic areas including:
- Antidiabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients.
- The company products include tablets, capsules, sprays, syrups, drops, powder, injections, cookies, ointments, and soft gels to treat pain, diabetes, cardiovascular, gynic, respiratory, neuroscience, and gastrointestinal disorders.
As of the latest available data, Eris Lifesciences Ltd has a market capitalization of ₹23,724 Crore. The company has demonstrated strong financial performance over the years, with revenues having grown 6x in the last 10 years (since FY11) and 2x in the last 5 years (since FY16). Additionally, net profits have grown ~ 17x in the last 10 years and 2.6x in the last 5 years.
For the financial year 2024-25, sales rose 44.59% to ₹2,879.26 Crore in the year ended March 2025, as against ₹1,991.30 Crore during the previous year ended March 2024. However, for the full year, net profit declined 10.26% to ₹351.84 Crore in the year ended March 2025, as against ₹392.05 Crore during the previous year ended March 2024.
For Q4 FY25, ERIS Lifesciences Ltd's revenue jumped 26.01% since last year same period to ₹713.31 Crore. ERIS Lifesciences Ltd's net profit jumped 32.11% since last year same period to ₹93.84 Crore.
In March 2024, we announced the acquisition of Biocon's India Branded Formulation business, thereby completing the second leg of our India Injectables strategy. The acquired business will add significant momentum to our organically built Insulin franchise with the addition of two Insulin power brands – Basalog and Insugen.
The acquisition also gave us an entry into the large and fast-growing segment of Oncology with a portfolio of monoclonal antibodies. This strategic move positions Eris for further expansion in high-growth therapeutic areas.
For FY26, the company anticipates revenue growth of 15% to 21%, translating to revenues in the range of ₹2,900-₹3,050 Crore. EBITDA for the segment is projected between ₹1,070 Crore and ₹1,130 Crore, with EBITDA margins maintained around 37%.
For FY26, the company projects an annual revenue addition of ₹200-₹300 Crore to its overall insulin franchise, beginning October 2025, driven by the insourcing of insulin production at its Bhopal facility.
Promoter holding in ERIS Lifesciences Ltd has gone down to 54.86% as of December 2024 from 54.90% as of March 2024. The company maintains strong corporate governance practices with an experienced board of directors and professional management team.
Eris Lifesciences has established itself as a formidable player in the Indian pharmaceutical market through its focused approach on chronic therapies, strong operational capabilities, and strategic acquisitions. The company's commitment to innovation and patient care, combined with its robust financial performance and growth prospects, positions it well for continued success in the competitive pharmaceutical industry.
